Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 3:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Multiple Myeloma
Interventions
KW-2478, Bortezomib
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
9
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 6 more
Conditions
Systemic Lupus Erythematosus
Interventions
belimumab, Placebo
Biological
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Conditions
Neoplasms
Interventions
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
64
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 56 more
Completed Phase 1 Interventional Accepts healthy volunteers

MEDI-557 Adult Dosing

NCT01562938
Conditions
Respiratory Syncytial Virus
Interventions
Placebo, MEDI-557
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miami, Florida
Conditions
Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer
Interventions
NPC-1C/NEO-102
Drug
Lead sponsor
Precision Biologics, Inc
Industry
Eligibility
18 Years to 99 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
6
States / cities
Tampa, Florida • Baltimore, Maryland • St Louis, Missouri + 3 more
Conditions
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Interventions
ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide
Genetic · Biological · Drug
Lead sponsor
Allogene Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
24
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 21 more
Recruiting Phase 4 Interventional Accepts healthy volunteers

Safety of RSV Preventive Monoclonal Antibody

NCT07158814
Conditions
Fever, Adverse Event Following Immunisation
Interventions
Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody
Drug
Lead sponsor
Duke University
Other
Eligibility
6 Weeks to 30 Weeks
Enrollment
524 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
6
States / cities
Oakland, California • Atlanta, Georgia • New York, New York + 2 more
Conditions
Mild Alzheimer's Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Interventions
Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
Drug
Lead sponsor
Centers for Medicare and Medicaid Services/ Coverage and Analysis Group
Federal
Eligibility
Not listed
Enrollment
8,680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
COVID-19, SARS-CoV-2
Interventions
VYD222 (pemivibart), Normal saline
Drug
Lead sponsor
Invivyd, Inc.
Industry
Eligibility
12 Years and older
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
18
States / cities
Fullerton, California • Long Beach, California • Rolling Hills Estates, California + 15 more
Conditions
Clostridium Infections
Interventions
GS-CDA1/MDX-1388, normal saline
Biological
Lead sponsor
MassBiologics
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
22
States / cities
Los Angeles, California • Oakland, California • Newark, Delaware + 18 more
Conditions
Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma, Monoclonal B-Cell Lymphocytosis, Small Lymphocytic Lymphoma, CLL (Chronic Lymphocytic Leukemia)
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 110 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Lymphoma
Interventions
apolizumab
Biological
Lead sponsor
PDL BioPharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Freemont, California
Conditions
Neuroblastoma
Interventions
beta-glucan, monoclonal antibody 3F8
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 49 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
New York, New York
Conditions
Renal Cell Carcinoma, Kidney Cancer
Interventions
Capecitabine, Gemcitabine, Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Relapsed/Refractory Large B Cell Lymphoma, Relapsed/Refractory Follicular Lymphoma
Interventions
ALLO-501, ALLO-647, Fludarabine, Cyclophosphamide
Genetic · Biological · Drug
Lead sponsor
Allogene Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Gilbert, Arizona • Stanford, California • Denver, Colorado + 4 more
Conditions
Solid Tumors
Interventions
BMS-986156, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
Birmingham, Alabama • La Jolla, California • Atlanta, Georgia + 4 more
Conditions
Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor B-cell Lymphoblastic Leukemia-Lymphoma
Interventions
SGN-CD19A
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
12 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Birmingham, Alabama • Duarte, California • Stanford, California + 3 more
Conditions
Healthy Adult Immune Responses to Vaccine
Interventions
VRC-EBOMAB092-00-AB (MAb114)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Eosinophilic Esophagitis
Interventions
CC-93538, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
12 Years to 75 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
115
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 97 more
Conditions
Liver Cancer
Interventions
Bevacizumab, Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Houston, Texas
Conditions
Diffuse Large B Cell Lymphoma
Interventions
Tafasitamab, Lenalidomide
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Morristown, New Jersey • Dallas, Texas • Olympia, Washington
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Nonneoplastic Condition, Precancerous Condition
Interventions
tanespimycin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Bethesda, Maryland
Conditions
Lung Cancer
Interventions
Avastin, Tarceva
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Conditions
Lymphoma
Interventions
rituximab, yttrium Y 90 ibritumomab tiuxetan
Biological · Radiation
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
3
States / cities
Birmingham, Alabama • Stanford, California • Rochester, Minnesota